Low-dose lobeglitazone effective against type 2 diabetes, study finds Medha Baranwal16 Sept 2022 11:00 AM ISTSouth Korea: The addition of low-dose lobeglitazone to the combination of metformin and DPP4 inhibitor versus standard-dose lobeglitazone led to...
Expanded dulaglutide weekly doses at par with 1.5 mg dose in type 2 diabetes with CVD risk: Study Medha Baranwal14 Sept 2022 10:45 AM ISTUSA: Findings from a post-analysis of the AWARD-11 study have suggested similar favorable effects of dulaglutide 3.0 mg and 4.5 mg on several...
Mean HbA1c and HbA1c variability help predict diabetes-related complications: Study Medha Baranwal13 Sept 2022 8:00 PM ISTTaiwan: Both standard deviation of HbA1c (HbA1c-SD) and mean HbA1c (HbA1c-mean) are associated with diabetes-related complications in type 2 diabetes...
Dapagliflozin improves myocardial reserve flow in type 2 diabetes patients: DAPAHEART Trial Dr. Kamal Kant Kohli13 Sept 2022 11:00 AM ISTSGLT-2 inhibition in type 2 diabetes patients increases myocardial flow reserve (MFR). ITALY: According to a recent study published in the...
'Liberal' approach to blood sugar control does not improve outcomes in diabetics admitted to ICU: Study Medha Baranwal12 Sept 2022 8:00 PM ISTAustralia: A 'liberal' approach to blood sugar targets reduces the risk of hypoglycemia but did not enhance patient-centered outcomes in type 2...
Semaglutide reduces diabetes risk by 61% in individuals with prediabetes or normal blood sugar levels Dr. Kamal Kant Kohli12 Sept 2022 11:29 AM ISTSemaglutide has recently been approved in US as an obesity treatment and has been provisionally approved to treat obesity in England. According to a...
Rare case of Fungal Ball in Urinary Bladder reported in NEJM Dr. Kamal Kant Kohli12 Sept 2022 9:00 AM ISTDr Chieh-Ying Chang and Ming-Han Hsieh have reported a rare case of fungal ball in Urinary Bladder that has been published in New England journal of...
Liver function markers predict cardiovascular and renal risk: CANVAS trial Medha Baranwal11 Sept 2022 8:00 PM ISTUSA: Higher levels of gamma-glutamyl transferase (γGT) may independently predict death risk and high CV risk, while canagliflozin protected against HF...
Empagliflozin proves beneficial in acute myocardial infarction: EMMY trial Dr. Kamal Kant Kohli11 Sept 2022 7:30 PM ISTAUSTRIA: Acute myocardial infarction (MI) patients who receive the SGLT2 inhibitor empagliflozin (Jardiance) early after the MI have improved markers...
Use of some diabetes drugs linked to risk of acute gallbladder disease, FDA reports Medha Baranwal7 Sept 2022 11:15 AM ISTPatients who take glucagon-like peptide-1 receptor agonists for weight loss or management of diabetes may be at risk of acute gallbladder...
AstraZeneca Forxiga gets Chinese nod to treat CKD with and without type 2 diabetes Ruchika Sharma6 Sept 2022 11:15 AM ISTForxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor.
Anaemia, mental disorders, pneumonia, GI disorders top list of hospitalization causes due to diabetes Dr. Kamal Kant Kohli5 Sept 2022 10:45 AM ISTWith changing lifestyle of Diabetics and disease profile of diabetes most common reasons why people with type 2 diabetes (T2DM) are admitted to...
